Typhoid Vi Polysaccharide Vaccine Market Landscape to 2034: Key Forces Shaping the Next Decade of Growth

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

How Large Will the Typhoid Vi Polysaccharide Vaccine Market Size By 2025?
In recent times, the market size for the typhoid vi polysaccharide vaccine has experienced rapid expansion. The market is projected to swell from $5.78 billion in 2024 to $6.77 billion in 2025, reflecting a compound annual growth rate (CAGR) of 17.1%. Factors contributing to the growth during the historic period include the prevalence of the disease, worldwide health initiatives, vaccination for travelers, government-driven immunization campaigns, and the effectiveness and safety of the vaccine.

How Big Is the Typhoid Vi Polysaccharide Vaccine Market Size Expected to Grow by 2029?
The market for typhoid vi polysaccharide vaccines is predicted to experience swift expansion in the coming years, with projected growth to $13.36 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 18.5%. The anticipated growth during this forecast period can be linked to the expansion of immunization programs, a global emphasis on health policies, epidemiological surveillance, an increase in demand in the travel medicine sector, and social and environmental influences. Key trends for the forecast period encompass investments in R&D, regulatory backing, epidemiological research, and public health education.

View the full report here:
https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

Which Key Market Drivers Powering Typhoid Vi Polysaccharide Vaccine Market Expansion and Growth?
The escalation in typhoid cases is anticipated to boost the typhoid VI polysaccharide vaccine market's expansion. Typhoid, a life-threatening infection, is induced by the bacteria Salmonella typhi and commonly transmitted via infected food or beverages. The Typhoid Vi polysaccharide vaccine is employed to protect adults and children aged 2 and older from typhoid fever instigated by Salmonella enterica serovar Typhi, or S. Typhi. For example, records from the UK Health Security Agency, a government organization, in August 2024 showed a surge in laboratory-validated symptomatic enteric fever incidents in England, Wales, and Northern Ireland from 2021 to 2022. The cases of S. Typhi spiked from 108 to 313, S. Paratyphi A from 31 to 135, and S. Paratyphi B from 13 to 18. Consequently, this uptick in typhoid incidence is fueling the growth of the typhoid Vi polysaccharide vaccine market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Typhoid Vi Polysaccharide Vaccine Market?
Establishing strategic alliances has emerged as a significant trend in the typhoid Vi polysaccharide vaccine industry. To consolidate their market position, key players in the typhoid Vi polysaccharide vaccine landscape are forming partnerships. For instance, in July 2022, The International Vaccine Institute, a South Korean organization specializing in infectious diseases with worldwide health impact including cholera, typhoid, shigella, and salmonella, joined forces with Moderna, the US biopharmaceutical firm. This collaboration resulted in the creation of the world's first cost-effective oral cholera vaccine and an advanced typhoid conjugate vaccine.

What Are the Emerging Segments in the Typhoid Vi Polysaccharide Vaccine Market?
The typhoid vi polysaccharide vaccine market covered in this report is segmented -

1) By Type: Child, Adult
2) By Route Of Administration: Oral, Parenteral
3) By Application: Government Institution, Private Sector, Other Applications

Subsegments:
1) By Child: Pediatric Formulations, Age-Specific Dosages
2) By Adult: Standard Adult Formulations, High-Risk Population Formulations

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=8313&type=smp

Who Are the Global Leaders in the Typhoid Vi Polysaccharide Vaccine Market?
Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Emergent Biosolutions Inc., PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bio-Med Pvt. Ltd., LG Chem, SK Chemicals Co. Ltd., Crucell Switzerland AG, Hualan Biological Engineering Inc., Indian Immunologicals Limited

Which are the Top Profitable Regional Markets for the Typhoid Vi Polysaccharide Vaccine Industry?
Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2024. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8313

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.